First order from France

Pharmacolog’s distributor has ordered a first system to be placed at Hôspital du Confluent in Nantes. The system shall be used for the final control of chemotherapy drugs toxicity at the hospital pharmacy. Pharmed won the order in competition with other suppliers.

During 2016, Pharmed has deliberately processed the French market, focusing on hospital pharmacies that prepare for chemotherapy and has now placed the first order on a DrugLog system. The system will be placed at the Hôspital du Confluent in Nantes and will be used for the final control of chemotherapy drugs prepared made at the hospital pharmacy. The deal means that, according to agreement, Pharmed purchases a DrugLog® systems from Pharmacolog for delivery to the hospital and results in a certain turnover impact.

CEO Mats Högberg comments: “It is extremely pleasing that Pharmed managed to get his first order. Key benefits that played an important role for the decision was DrugLog’s speed and ease of use. Then, of course, it’s extra satisfying to win a deal where we competed against a domestic French competitor. The deal is a result of the purposeful and long-term work of our Pharmed distributor, which is now beginning to show results. ”

Didier Dubois, Sales Manager at Pharmed SAM: “We have been working methodically in introducing the DrugLog concept in France and are very happy to be able to close our first deal. The interest for DrugLog is increasing and our sales funnel steadily growing. There is definitely a strong demand for efficient solutions for validation of chemo drugs in the French market so we have great hope that Nantes will be followed by many others.”

Pharmacolog signs agreement with B. Braun S.A.

Pharmacolog has entered into an agreement with B. Braun Medical S.A Spain concerning exclusive distribution of DrugLog® on the Spanish market. The agreement also considers the future integration of DrugLog® with one of the company’s software Oncology technologies.

Braun Medical S.A. Spain is a company within the B. Braun Group engaged, among other activities, in the product development in the field of Injectable Drug Delivery. The area includes developing new solutions for managing the entire process of chemotherapy with cytotoxic drugs, from prescription to patient infusion. The agreement signed between Pharmacolog and B. Braun Medical Spain means that B. Braun acts as an exclusive distrib...

Pharmacolog kallar till bolagsstämma

Aktieägarna i Pharmacolog i Uppsala AB (publ), 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.

Anmälan m.m.

Aktieägare som önskar delta vid årsstämman skall:

–    dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och

–    dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till

Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (ell...

Continued negotiations with international MedTech Group

In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.

The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quar...

Extended collaboration with Uppsala University regarding dosage of antibiotics

Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.

The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.

Hans Dahlin, Research Director and Founder, comments: R...